Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients
Open Access
- 17 December 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 52 (2), 248-256
- https://doi.org/10.1093/cid/ciq104
Abstract
Background. Few data are available regarding the immunogenicity and safety of the pandemic influenza vaccine in immunocompromised patients. We evaluated the humoral response to the influenza A H1N1/09 vaccine in solid-organ transplant (SOT) recipients, in patients with human immunodeficiency virus (HIV) infection, and in healthy individuals. Methods. Patients scheduled to receive the pandemic influenza vaccine were invited to participate. All participants received the influenza A H1N1/09 AS03-adjuvanted vaccine containing 3.75 μg of hemagglutinin. SOT recipients and HIV-infected patients received 2 doses at 3-week intervals, whereas control subjects received 1 dose. Blood samples were taken at day 0, day 21, and day 49 after vaccination. Antibody responses were measured with the hemagglutination inhibition assay (HIA) and a microneutralization assay. Results. Twenty-nine SOT recipients, 30 HIV-infected patients, and 30 healthy individuals were included in the study. Seroconversion measured by HIA was observed in 15 (52%) of 29 SOT recipients both at day 21 and day 49; in 23 (77%) of 30 at day 21 and 26 (87%) of 30 at day 49 in HIV-infected patients, and in 20 (67%) of 30 at day 21 and in 23 (77%) of 30 at day 49 in control subjects (P = .12 at day 21 and P = .009 at day 49, between groups). Geometric means of antibody titers were not significantly different between groups at day 21 or at day 49. Conclusions. Influenza A H1N1/09 vaccine elicited a similar antibody response in HIV-infected individuals and in control subjects, whereas SOT recipients had an overall lower response. A second dose of the vaccine only moderately improved vaccine immunogenicity in HIV-infected patients.Keywords
This publication has 24 references indexed in Scilit:
- Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort studyThe Lancet Infectious Diseases, 2010
- Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre studyBMJ, 2010
- Clinical Aspects of Pandemic 2009 Influenza A (H1N1) Virus InfectionThe New England Journal of Medicine, 2010
- Guidance on Novel Influenza A/H1N1 in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2010
- A Novel Influenza A (H1N1) Vaccine in Various Age GroupsThe New England Journal of Medicine, 2009
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineThe New England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineThe New England Journal of Medicine, 2009
- Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in childrenThe Lancet, 2009
- H1N1 2009 influenza virus infection during pregnancy in the USAThe Lancet, 2009
- Historical Perspective — Emergence of Influenza A (H1N1) VirusesThe New England Journal of Medicine, 2009